| Identification | Back Directory | [Name]
BENZAMIDE, 4-METHOXY-N-[2-[2-(1-METHYL-2-PIPERIDINYL)ETHYL]PHENYL]- | [CAS]
66778-36-7 | [Synonyms]
Enkade
Enkaid
MJ-9067
M-9067-1
Encainida
Encainidum
Brn 0497572
MJ-9067[AS BASE]
Encainide [french]
Encainida [spanish]
4-Methoxy-2'-[2-(1-methyl-3-piperidyl)ethyl]benzanilide
BENZAMIDE, 4-METHOXY-N-[2-[2-(1-METHYL-2-PIPERIDINYL)ETHYL]PHENYL]-
(±)-4-Methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]phenyl]benzamide | [Molecular Formula]
C22H28N2O2 | [MDL Number]
MFCD00864726 | [MOL File]
66778-36-7.mol | [Molecular Weight]
352.47 |
| Hazard Information | Back Directory | [Chemical Properties]
Pale yellow crystals. Soluble in ether, insoluble in saturated saline. Encainide Hydroehloride: C????H????N??O??·HCl. [66794-74-9]. White crystals, melting point 131.5-132.5°C. Freely soluble in water, slightly soluble in alcohol, insoluble in ether or pentane. Acute toxicity LD50 values in mice and dogs (mg/kg): 86, 43 mg/kg oral; 16, 17 mg/kg intravenous. | [Uses]
Encainide (MJ9067) is an antiarrhythmic agent with class IC activity. Encainide blocks voltage-dependent potassium channels. Encainide has the potential for life-threatening ventricular arrhythmias, symptomatic ventricular arrhythmias and supraventricular arrhythmias research[1][2]. | [Definition]
ChEBI: 4-Methoxy-N-phenylbenzamide in which the hydrogen at the 2 position of the phenyl group is substituted by a 2-(1-methylpiperidin-2-yl)ethyl group. A class Ic antiarrhythmic, the hydrochloride was used for the treatment of severe or life-
hreatening ventricular arrhythmias, but it was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack and was withdrawn from the market. | [in vivo]
Encainide (0.3, 0.9, 2.7 mg/kg; infusion of single doses) prolongs His-Purkinje conduction time (HV interval) and intra-ventricular conduction time (QRS duration) but has no effect on sinus nodal recovery time or AV nodal conduction, or on refractoriness of atrium, AV node, or ventricular myocardium or on QT interval[1]. | [References]
[1] R N Brogden, et al. Encainide. A review of its pharmacological properties and therapeutic efficacy. Drugs. 1987 Nov;34(5):519-38. DOI:10.2165/00003495-198734050-00002
[2] Hongliang Li, et al. Encainide, a class Ic anti-arrhythmic agent, blocks voltage-dependent potassium channels in coronary artery smooth muscle cells. Korean J Physiol Pharmacol. 2023 Jul 1;27(4):399-406. DOI:10.4196/kjpp.2023.27.4.399 |
|
|